Bristol-Myers Squibb (BMY)
$66.68
0.66 (1.00%)
12:59 EST
BMY Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
108.99B
PE Ratio
116.98
EPS
0.57
Volume (Avg. Vol.)
4.95M
Day's Range
65.54 - 66.86
52-Week Range
45.76 - 68.34
Dividend & Yield
1.60 (2.40%)
BMY Stock Predictions, Articles, and Bristol-Myers Squibb News
- From InvestorPlace
- From the Web
7 Pharmaceutical Stocks With Exciting Plans for 2021
Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.
The Top 7 Pharmaceutical Stocks for the Next 10 Years
By
Alex Sirois
Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.
7 Cheap Stocks to Buy in January For a Quick Buck
By
Alex Sirois
2020 has taken the market capitalizations of many strong companies to lows. That means there are some great options for cheap stocks to buy in January.
7 Cheap Stocks That Can’t Wait for 2021
Cheap stocks have always intrigued investors because we always want a bargain. So, here are seven cheap stocks to buy now.
7 Undervalued Stocks to Buy Now
Everyone is on the hunt for undervalued stocks. Keep in mind, even more highly valued stocks can be undervalued. Let's look at seven of them.
3 Cheap Dividend Stocks For High Total Returns
Cheap dividend stocks can generate a double dose of returns, with dividends as well as capital appreciation through a rising share price.
7 Pharmaceutical Stocks to Buy for 2021 and Beyond
Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives. With them, we can solve Covid-19.
7 Healthcare Stocks That Can Survive Massive Reform
These seven healthcare stocks may represent robust long-term investments no matter how reforms in the sector may develop post-election.
7 Cutting-Edge Biotech Stocks for Tomorrow
Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.
M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers Squibb Deal
MyoKardia's major, $13.1 billon deal with fellow pharmaceutical company Bristol Myers Squibb sent MYOK stock soaring on Monday.
This Company is the Landlord of Life Sciences
Alexandria Real Estate Equities is the largest landlord in the US for laboratories and related offices.
5 Top Stock Trades for Friday: UBER, FB, BMY, MU, TWLO
Bristol-Myers Squibb, Uber, Facebook, Micron and Twilio were our top stock trades for Friday. That said, let's look at the charts now.
Bristol-Myers Squibb Earnings: BMY Stock Jumps 2% on Q2 Beats
Bristol-Myers Squibb earnings on Thursday have BMY stock rising higher after the company beat EPS and revenue estimates from Wall Street.
Bristol-Myers Squibb Is a Dirt-Cheap Buy Before Earnings
Thanks to its Celgene acquisition, Bristol-Myers Squibb looks attractive ahead of earnings. Here's why you should buy BMY stock.
Bristol-Myers Squibb Has Great Potential Ahead of Earnings
Ahead earnings, Bristol-Myers Squibb is a great value play. In fact, BMY stock is worth 30%-70% more than its current share price.
5 Healthcare Stocks for Good (Portfolio) Health
These 5 healthcare stocks look like the sector's best, with downside protection and room for price appreciation even if the market falters.
Undervalued Bristol-Myers Squibb Stock Is Worth 50% More
BMY stock looks cheap here. Bristol-Myers is a defensive value with an attractive yield, cheap valuation, and plenty of potential upside.
10 Value Stocks to Keep on Your Short List
Value stocks have been out of favor for some time — but that will change at some point. When it does, these 10 names should be winners.
5 Healthcare Stocks That Are Profitable but Also Cheap
These five healthcare stocks have low P/E ratios and ample yields, making them cheap and profitable options for investors.
3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline
Friday's big stock charts feature pharmaceutical-market names that recently posted terrific earnings data.

Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
Sell